A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro.
A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro.
复制标题
新型恶唑烷酮 Contezolid (MRX-I) 在体外具有抗脓肿分枝杆菌活性。
DOI：
10.1128/aac.00889-21
复制
发表时间：
2021-10-18
影响因子：
4.9
通讯作者：
Chu H
中科院分区：
文献类型：
--
作者：
Guo Q;Xu L;Tan F;Zhang Y;Fan J;Wang X;Zhang Z;Li B;Chu H
对一种新型噁唑烷酮类药物康泰唑胺（MRX - I）针对12株标准菌株和194株临床分离株所表现出的抗脓肿分枝杆菌活性进行了评估。康泰唑胺在体外对脓肿分枝杆菌有活性，其在细胞外和细胞内的抗脓肿分枝杆菌效果与利奈唑胺相当。康泰唑胺不会拮抗最常用的抗脓肿分枝杆菌药物，并且预先接触康泰唑胺不会诱导耐药性。这些结果为治疗脓肿分枝杆菌感染提供了一种新的方法。
An evaluation of the anti-Mycobacterium abscessus activity expressed by a novel oxazolidinone, contezolid (MRX-I), toward 12 reference strains and 194 clinical isolates was conducted. Contezolid was active against M. abscessus in vitro, with effects comparable to the anti-M. abscessus effects of linezolid both extracellularly and intracellularly. Contezolid did not antagonize the most frequently used anti-M. abscessus drugs, and preexposure to contezolid did not induce drug resistance. These results provide a novel approach to treating M. abscessus infections.